Global and China Monoclonal Antibody Industry Report, 2013 - 2017
Published Date » 2013-12-23
No. Of Pages » 118
Currently, monoclonal antibody agents have been successfully used in the treatment of tumors, cancers and other serious diseases as a heavyweight in the biopharmaceutical industry. In 2009-2012, the market size of monoclonal antibody agents grew at a CAGR of 13%, far higher than the overall growth rate of biopharmaceuticals in the same period. Thanks to robust market demand, approval of new products and new indications as well as launch of monoclonal antibody generic drugs, the global monoclonal antibody market size will ascend by more than 12% in 2013-2017, hitting USD141 billion in 2017.
Driven by enhanced economic level, expanded scope of medical insurance reimbursement, as well as lower prices incurred by intensified competition, Chinese monoclonal antibody market is expected to continue to grow significantly. In 2013-2017, Chinese monoclonal antibody market will grow at 35%, sharing 21.5% of the global monoclonal antibody market in 2017 (9.5% in 2012).
The global monoclonal antibody industry is still dominated by European and American companies, especially, important monoclonal antibody products are mainly produced by Roche (Genentech), Amgen, AbbVie (Abbott), Johnson & Johnson and other companies. In 2012, the global best-selling Infliximab (Johnson & Johnson), Etanercept (Amgen), Bevacizumab (Roche), Rituximab (Roche), Adalimumab (AbbVie) and Trastuzumab (Roche) stemmed from the above four companies. The global sales (including the sales of third parties) of these six monoclonal antibody agents totaled USD45 billion, accounting for 57.7% of the global.
Propelled by the optimistic market prospect, advancement of monoclonal antibody technologies and the upcoming patent expiration of several key monoclonal antibody agents, the research and industrialization of monoclonal antibody agents has become a global investment highlight, wherein the future market competition will be evident.
In September 2013, the Infliximab generic drug - Inflectra developed by South Korea Celltrion and the U.S. Hospira jointly was launched upon the approval of the EU EMA. In November 2013, the Trastuzumab generic drug developed by the U.S. Mylan and India Biocon together was available in the market under the permit of Drug Controller General Of India. Mylan will sell the product tagged with the brand name Hertraz in India in early 2014.
In addition, India Biocon's first anti-CD6 Alzumab (Itolizumab) for the treatment of chronic plaque psoriasis was approved to be sold in India in August 2013.
In recent years, China monoclonal antibody industry has been developing fast with the market size CAGR of 44.6% in 2010-2012. More than 100 companies have been involved in monoclonal antibody agents, and 10 ones of them have conducted clinical applications. The Chinese market is dominated by Rituximab, Trastuzumab, Infliximab, Bevacizumab and other imported products, all of which occupied 70-75% market share totally in 2012.
However, by virtue of price and geographical advantages, the competitiveness of Chinese local monoclonal antibody products has been gradually improved, such as the competition between Nimotuzumab and Cetuximab. The market share of Merck's Cetuximab in China shrinks and was excluded from top 200 drugs purchased by Chinese 22 typical urban hospitals in 2012 with the value of RMB130 million (down 16.35% year on year).
Meanwhile, the R & D of monoclonal antibody has also made progress. The Adalimumab generic drug developed by Huahai Pharmaceutical and American Oncobiologics jointly was ratified by the EU EMA and the U.S. FDA in December 2013 and the clinical trial Phase I was implemented. The Trastuzumab generic drug of Genor Biopharma was granted with Australian Clinical Preliminary Summary Report Phase I in August 2012 and SFDA's clinical trial approval in July 2013.
Table of Content
1 Overview of Monoclonal Antibody Industry
1.3 Technological Development
2 Overview of Global Monoclonal Antibody Industry
2.1 Status Quo
2.2 Market Size
2.3 Competition Pattern
2.4 Development Prospect and Prediction
2.4.1 Market Size
2.4.2 Competition Pattern
2.4.3 R & D Trend
3 Chinese Monoclonal Antibody Market
3.1 Status Quo
3.2 Market Size
3.3 Market Segments
3.3.6 Recombinant Human Tumor Necrosis Factor Receptor Type II - Antibody Fusion Protein
3.4 Competition Pattern
3.5 Development Prospect
4 Key Foreign Monoclonal Antibody Agent Enterprises
4.1 Roche Pharmaceuticals
4.1.3 Revenue Structure
4.1.4 R & D and Investment
4.1.5 Monoclonal Antibody Business (Genentech)
4.1.6 Business in China
4.2 Johnson & Johnson
4.2.3 Revenue Structure
4.2.4 R & D and Investment
4.2.5 Monoclonal Antibody Business
4.2.6 Business in China
4.3.3 Revenue Structure
4.3.4 R & D and Investment
4.3.5 Monoclonal Antibody Business
4.3.6 Business in China
4.4.3 Revenue Structure
4.4.4 R & D and Investment
4.4.5 Monoclonal Antibody Business
4.4.6 Business in China
4.5.2 Revenue Structure
4.5.3 R & D and Investment
4.5.4 Monoclonal Antibody Business
4.5.5 Business in China
4.6.3 Revenue Structure
4.6.4 R & D and Investment
4.6.5 Monoclonal Antibody Business
4.6.6 Business in China
5 Key Chinese Monoclonal Antibody Agent Enterprises
5.1 Shanghai Lansheng States Kin Pharmaceutical Co., Ltd.
5.1.2 Shanghai CP Guojian Pharmaceutical Co., Ltd.
5.1.3 Shanghai Zhangjiang Biotech Co., Ltd.
5.1.4 Shanghai CP GuoJian Biotech Academy
5.1.5 Shanghai Guosheng Pharmaceutical Co., Ltd.
5.2 Beijing Biotech Pharmaceutical Co., Ltd.
5.2.2 Competitive Edges
5.2.3 Development Prospect
5.3 Chengdu Huasun Group Co., Ltd.
5.3.2 Chengdu Huasun Biotech Co., Ltd.
5.4 Shanghai Medipharm Biotech Co., Ltd.
5.4.2 Monoclonal Antibody Business
5.5 Zhejiang Hisun Pharmaceutical Co., Ltd.
5.5.2 Monoclonal Antibody Business
5.6 Yunnan Walvax Biotechnology Co., Ltd.
5.6.2 Monoclonal Antibody Business
5.7 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
5.7.2 Monoclonal Antibody Business
5.8 Beijing SL Pharmaceutical Co., Ltd.
5.8.2 Monoclonal Antibody Business
5.9 Shenzhen Main Luck Pharmaceuticals Inc.
5.9.2 Monoclonal Antibody Business
5.10 Huahai Pharmaceutical Co., Ltd.
5.10.2 Monoclonal Antibody Business
6 Summary and Forecast
6.1 Comparison between Domestic and Foreign Companies
6.2 Market Forecast
List of Tables
List of Figures
Melamine Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
Melamine is an organic, heterocyclic compound containing nitrogen as a major constituent in its structure. Melamine products are highly flame retardant due to their high nitrogen content. Melamine is produced industrially on a large scale by either catalyzed gas phase or high pressure liquid phase reactions. In some cases, molten urea is passed over fluidized bed to carry out reaction with the help of catalysts. Melamine when reacted with formaldehyde forms melamine formaldehyde (MF) which shows excellent properties when crosslinked and has wide area of applications. On the basis...
Video Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
The video devices market is shifting the way users interact with their phones, televisions and computers. Video devices market includes video-enabled consumer electronic devices such as video game consoles, smart TVs, blue-ray players. In addition IP streaming devices, set top boxes and tablets are important segments of video devices market. Smart phones account for nearly half of total market units at present and is expected to continue to rule the global market over the forecast period. A constant shift toward long-form online video consumption has been motivating first-time...
Direct-To-Home (DTH) Satellite TV Services Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
Direct-To-Home (DTH) satellite television services have remarkably changed the mass electronic communication industry. DTH service provides reliable signals, high-definition video clarity, digital sound quality and essential signal security. It provides consumers with the facility to select the channels based on their preference and thus helping in cutting down on expenses. The broadcasters can also find out the exact number of viewers for a specific channel (TRP) to estimate its popularity. C-band and Ku-band are the two modes of DTH signal transmission. Increasing importance...
We will be happy to help you find what you need.
Please call us or write us:
Please call us or write us:
866-997-4948 (Us-Canada Toll Free)
Select License type:
Alternative Payment Method
- Global and China Digital Camera Industry 2014 Market Research Report
- Global and China Gypsum Industry 2014 Market Research Report
- Global and China Feldspar Industry 2014 Market Research Report
- Global and China Diatomite Industry 2014 Market Research Report
- Global and China Boron Industry 2014 Market Research Report
- Global and China Other Accessories & Parts Industry 2014 Market Research Report
- Global and China Cement Industry 2014 Market Research Report
- Global and China Microphone Industry 2014 Market Research Report
- Global and China Stickers & Skin Industry 2014 Market Research Report
- Global and China Memory Card Industry 2014 Market Research Report
Solar Power Generation Reaches Record High in the U.S. in 2013
Mar 6, 2014
Solar power accounted for an even larger share in the total volume of electricity generated in the United Sates in 2013. According to a latest report published by the Solar Energy Industries Association along with GTM Research suggests that this form of energy is increasingly becoming a part of the main stream U.S. power grid. So, it is not surprising that the production of solar...
Reynolds focus on Lorillard tobacco bid
Mar 5, 2014
U.S. tobacco giant - Reynolds American has stated a bid for its biggest rival Lorillard in the market. This bid has set quakes on the global tobacco market that is already being remodeled by declining smoking rates and growth of electronic cigarettes. Lorillard shares closed at 9.3 percent at $53.61 early Monday, giving a market value of $19.6bn. Reynolds bid could not be fairly...
Ecommerce to be New Growth Driver in Chinese Economy
Mar 4, 2014
Chinese ecommerce companies are set to make it big in the coming years with the market for ecommerce in China likely to grow to a whopping value of USD 8.17 trillion by 2020. This is what the vice-president of Alibaba estimates. China has largely been an export oriented society and it is online retail that is currently enabling the country to make a shift from this status. The...
Protect fruits from QFF flies
Mar 3, 2014
Queensland Fruit fly (QFF) is considered to be one of Australia’s intensely serious insect pests affecting the horticultural industry in the Central Tablelands and beyond. The Central Tablelands Local Land Services are knee-deep into testing a QFF monitoring program associated with the horticulturists in the Orange area. The authorities of this organization are open to...
Australian Companies Post Higher Profits Beating ExpectationsAustralian Companies Post Higher Profits Beating Expectations
Feb 28, 2014
Several large companies in Australia have beaten expectations by posting higher earnings and profits than expected. This is being regarded as one of the most positive reporting sessions since the last couple of years. The reporting session of February wrapped up with over 50% of the listed companies in Australia posting profits or beating expectations of earnings. Though there...